OKYO Pharma Limited (OKYO NASDAQ) stock market data APIs
$1.4745
0(0%)
as of October 6, 2026
Try our APIs with
free plan!
OKYO Pharma Limited Financial Data Overview
Price chart is built with
Anychart
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Prev. Close
1.4745
Open
1.4747
High
1.4967
Low
1.4726
52 wk Range
1.2648-3.2
Market Cap
76 620 K
Shares Outstanding
52 480 K
Beta
-0.058
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OKYO Pharma Limited data using free add-ons & libraries
Get OKYO Pharma Limited Fundamental Data
OKYO Pharma Limited Fundamental data includes:
- Net Revenue:
- EBITDA: -8 497 733
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OKYO Pharma Limited News
New
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuro...
OKYO Pharma Announces Purchase of Shares by Chairman
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuro...
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans Proactive uses images sourced from Shutterstock OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed i...
Dow drops 300 points as chip rally fades ahead of Big Tech earnings
4:20pm: Early rally fades US stocks finished mixed on Monday as an early rally lost steam, with investors taking some profits in semiconductor stocks ahead of a pivotal week of Big Tech earnings whi...
Get OKYO Pharma Limited fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.